News
With regard to the choice of bone-protecting agent, denosumab (Xgeva) improved bone density and reduced fracture risk in a placebo-controlled trial involving men with non-metastatic HSPC. Denosumab ...
DynaCAD urology with advanced annotation UroNav cart with advanced annotation option UroNav with advanced annotation July 23, 2025 Supporting prostate cancer diagnosis with more precise guidance for ...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options ...
Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...
Finding cancer early makes it much more likely that treatment will work. There are early signs of cancer that are easy to ...
Pharmaceutical scientists, clinicians, nurses and pharmacists from the National University of Singapore (NUS) and National University Hospital (NUH) have shown that a reduced dose of abiraterone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results